As with previous lung cancer data, the second anti-EGFR biotinylated antibody bPan behaves similarly as bCet in FaDu, suggesting that engagement of EGFR by any AvidinOX-anchored anti-EGFR antibody might lead to the same outcome. This evidence concerns the gene EGFR and lung carcinoma.